KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 1.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,424 | +167.0% | 8,874 | +477.7% | 0.00% | – |
| Q2 2023 | $4,654 | -96.9% | 1,536 | -93.6% | 0.00% | – |
| Q1 2023 | $149,000 | +136597.2% | 23,880 | +33.3% | 0.00% | – |
| Q4 2022 | $109 | -100.0% | 17,918 | -6.1% | 0.00% | – |
| Q3 2022 | $228,000 | +3.2% | 19,074 | +9.0% | 0.00% | – |
| Q2 2022 | $221,000 | -10.2% | 17,507 | -19.9% | 0.00% | – |
| Q1 2022 | $246,000 | -23.4% | 21,870 | +20.7% | 0.00% | – |
| Q4 2021 | $321,000 | +3.9% | 18,114 | +35.0% | 0.00% | – |
| Q3 2021 | $309,000 | +63.5% | 13,418 | +64.7% | 0.00% | – |
| Q2 2021 | $189,000 | +19.6% | 8,147 | +60.8% | 0.00% | – |
| Q1 2021 | $158,000 | – | 5,068 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |